Compare Regeneron Pharmaceuticals Inc (REGN) vs Rockwell Automation (ROK) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.

Rockwell Automation (ROK) trades at $434.14, down 3.68% on the day, with a bullish technical signal from moving averages. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue for 2025 was $8.34 billion, with a net income margin of 13.38%. Recent news highlights its leadership in industrial automation and digital transformation, including partnerships in AI-enabled cyber defense.

The outlook is supported by strong profitability and analyst consensus, but high valuation multiples and competitive pressures pose risks. The consensus price target of $489.89 suggests potential upside, though investors should monitor earnings sustainability and macroeconomic factors affecting industrial demand.